AMLX Stock — Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX)

Updated October 16, 2026.

AMLX is a Stock. Total return is 45.8% over the past 4.8 years, 28.7 points behind SPY at 74.5%.

Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing treatments for neurodegenerative diseases and endocrine conditions, with a pipeline that includes Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism in phase 3 trials, along with several earlier-stage candidates targeting conditions such as wolfram syndrome, progressive supranuclear palsy, and amyotrophic lateral sclerosis. The company does not currently distribute dividends. This security appeals primarily to investors with high risk tolerance who are interested in early-stage drug development and the potential for significant capital appreciation or loss based on clinical trial outcomes.

AMLX performance versus SPY

Price and return data through 2026-10-16.

Total return is 45.8% over the past 4.8 years, 28.7 points behind SPY at 74.5%. Over the past year its total return — price change plus distributions reinvested — is 73.6%. Its deepest 1-year drawdown was 33.6%.

AMLX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/07/2022

Distribution frequency

None

Last close

$26.34 (as of 2026-10-16)

Market cap

$3,306,013,684

Average volume

1150556.0

Beta

-0.092

Payout ratio

0.0%

Forward P/E

2.7739

EPS

$-1.41

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AMLX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 33.6%.

Who may consider AMLX — and who may not

It is a weaker fit for investors who need monthly cash flow (AMLX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AMLX

• All tickers starting with A

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions